Skip to content

National Hypertension Taskforce takes on the silent killer of uncontrolled blood pressure in Australia

The Australian Cardiovascular Alliance (ACvA) and Hypertension Australia (formerly the High Blood Pressure Research Council of Australia) have joined forces to establish a National Hypertension Taskforce with the ambitious goal to double Australia’s rates of controlled blood pressure from 32% to 70% by 2030. “If all Australians currently living with high blood pressure were properly …

Best evidence yet that lowering blood pressure can prevent dementia

A global study of over 28,000 people has provided the strongest evidence to date that lowering blood pressure in later life can cut the risk of dementia. Dr Ruth Peters, Associate Professor at UNSW Sydney and Program Lead for Dementia in The George Institute’s Global Brain Health Initiative, said that in the absence of significant …

Medisanté and George Medicines bring Internet of Things (IoT) data collection to decentralised Phase III trial

Remote cellular-enabled blood pressure monitoring provides novel and secure way of collecting real world data (RWD) in decentralised global phase III pivotal study. Unique remote device monitoring (RDM) capabilities of Medisanté’s medical IoT platform (M+ Hub) enhance George Medicines’ clinical trial management system. Seamless decentralised data collection of blood pressure measurements over a secure private cellular …

George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial

Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage development with global Phase III trials underway Single-pill triple combination outperformed standard treatments without additional adverse effects in earlier clinical research VERONICA-Nigeria trial aims for more than 80% blood pressure control while improving cost-effectiveness in treating hypertension, providing a potential valuable tool to address the growing …

Triple combination candidate GMRx4 advances into Phase II clinical development for first-line treatment of type 2 diabetes

GMRx4 is the second candidate to be prioritised in Company’s pipeline of proprietary fixed-dose combination therapies targeting non-communicable diseases George Medicines receives $1.5 million investment from Australia’s national biotechnology incubator CUREator London, UK, 20 July 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes …

Private Public Partnership to Fast Track Treatments for Rare Cancers Receives Backing from the Australian Government

A new multi-faceted partnership supported by George Clinical will move to the forefront of the cancer treatment revolution. The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub building links from research through to the clinic; creating jobs and changing lives. Over the past decade, immunotherapy and other …

New low-cost dialysis system can make medical grade water in the home, giving green light to progress to clinical trials

LONDON | 27 FEBRUARY   Findings from preliminary tests of a new dialysis system have confirmed its ability to make sterile, medical grade water to provide an affordable, accessible home-based treatment option for patients with kidney failure. This means that the Ellen Medical Devices Point-of-Care dialysis system can create peritoneal dialysis fluid (a mix of sterile …

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to substantially increase efficacy and improve adherence to treatment, while minimising side effects London, UK, January 17 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, …

New hope for kidney patients around the world with investment into Australian dialysis device manufacture

Sydney-based start-up Ellen Medical Devices will receive $427,500 in government funding that will be matched by the company, making a total investment of $1.04 million to develop its award-winning Ellen Medical Dialysis System. The investment is part of the Advanced Manufacturing Growth Centre’s (AMGC) $30 million Commercialisation Fund supporting innovative Australian businesses to grow their manufacturing …

George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director

London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director. Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader. Prior …